The significant cash raise offsets the negative revenue and earnings trends, positioning Inventiva to reach its pivotal NATiV3 data readout in Q4 2026 without immediate dilution risk. Traders should monitor the upcoming Q1 2026 financial update for cash burn trends and prepare for potential volatility around the NATiV3 topline results. The odiparcil sale de-risks part of the pipeline but offers only optionality.
Price Chart
Executive Summary
Inventiva reported 2025 full-year results with revenues declining to $4.5 million from $9.2 million in 2024, driven by lower licensing income. The company raised $172.5 million in a U.S. public offering and now holds $230.9 million in cash and short-term deposits, extending its cash runway into Q1 2027. Despite a wider net loss of $354.1 million, the funding provides runway through the expected Q4 2026 topline readout of its pivotal NATiV3 trial for lanifibranor in MASH. The sale of odiparcil adds potential future milestone and royalty upside.
Key Facts
- Revenues declined to $4.5 million in 2025 from $9.2 million in 2024, primarily due to lower licensing income from CTTQ.
- Cash and short-term deposits totaled $230.9 million ($99.3M cash + $131.6M deposits) as of December 31, 2025.
- Raised $172.5 million in gross proceeds from a U.S. public offering in November 2025, plus $115.6 million from a structured financing tranche.
- Cash runway expected through mid-Q1 2027; could extend to Q3 2027 if Tranche 3 warrants are exercised for up to $116 million.
- Net loss widened to $354.1 million in 2025 from $184.2 million in 2024, driven by non-cash financial losses related to derivative accounting.
- Completed sale of odiparcil to Biossil, Inc. for $600,000 upfront and potential future milestones of up to $90 million and high single-digit royalties.
- Topline results from the NATiV3 Phase 3 trial expected in Q4 2026.
Financial Impact
Revenue declined by 51% YoY to $4.5 million; net loss more than doubled to $354.1 million. However, financing activities generated $241.3 million in net cash, significantly strengthening the balance sheet.
Risk Factors
- Widening net loss and reliance on non-cash accounting charges may concern investors despite strong cash position.
- Failure of the NATiV3 trial in Q4 2026 would severely impact valuation, as lanifibranor is the lead asset.
- Future funding depends on warrant exercises or new capital raises if milestones aren't met.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-002025 |
| Document: f6k_033026.htm | 0001171843-26-002025 |
| Document: 0001171843-26-002025-index-headers.html | 0001171843-26-002025 |
| Document: 0001171843-26-002025-index.html | 0001171843-26-002025 |
| Document: 0001171843-26-002025.txt | 0001171843-26-002025 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 9, 2026 20w ago | 6-K | $5.33 $3.59 | ▼ −32.65% | ▼ −39.50% | $3.18 (−40.34%) |
Jun 3, 2026 20w ago | 6-K | $5.33 $3.59 | ▼ −32.65% | ▼ −35.14% | $3.18 (−40.34%) |
Jun 2, 2026 20w ago | 6-K | $5.33 $3.59 | ▼ −32.65% | ▼ −35.14% | $3.18 (−40.34%) |
May 26, 2026 22w ago | 6-K | $5.33 $3.59 | ▼ −32.65% | ▼ −34.52% | $3.18 (−40.34%) |
May 22, 2026 22w ago | 6-K | $5.33 $3.59 | ▲ +32.65% | ▲ +35.37% | $3.18 (+40.34%) |
Apr 8, 2026 28w ago | 20-F | $5.50 $3.59 | ▲ +34.73% | ▲ +45.18% | $3.18 (+42.18%) |
Mar 30, 2026 30w ago | 6-K | $5.50 $3.59 | ▼ −34.73% | ▼ −47.11% | $3.18 (−42.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers